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Highlights 
 An epigenome-wide association study including 3000 individuals from four cohorts was 
performed 
 DNA methylation within 5 genomic locations is associated with IgG glycosylation 
 DNA methylation mediated the effects of smoking on IgG glycosylation 
 
Abstract 
Background: Glycosylation is one of the most common post-translation modifications with large 
influences on protein structure and function. The effector function of immunoglobulin G (IgG) alters 
between pro- and anti-inflammatory, based on its glycosylation. IgG glycan synthesis is highly 
complex and dynamic.  
Methods: With the use of two different analytical methods for assessing IgG glycosylation, we aim to 
elucidate the link between DNA methylation and glycosylation of IgG by means of epigenome-wide 
association studies. In total, 3,000 individuals from 4 cohorts were analyzed.  
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Results: The overlap of the results from the two glycan measurement panels yielded DNA 
methylation of 7 CpG-sites on 5 genomic locations to be associated with IgG glycosylation: 
cg25189904 (chr.1, GNG12); cg05951221, cg21566642 and cg01940273 (chr.2, ALPPL2); cg05575921 
(chr.5, AHRR); cg06126421 (6p21.33); and cg03636183 (chr.19, F2RL3). Mediation analyses with 
respect to smoking revealed that the effect of smoking on IgG glycosylation may be at least partially 
mediated via DNA methylation levels at these 7 CpG-sites. 
Conclusion: Our results suggest the presence of an indirect link between DNA methylation and IgG 
glycosylation that may in part capture environmental exposures. 
General Significance: An epigenome-wide analysis conducted in four population-based cohorts 
revealed an association between DNA methylation and IgG glycosylation patterns. Presumably, DNA 
methylation mediates the effect of smoking on IgG glycosylation. 
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Introduction 
Functional diversity of the proteome is mainly achieved by post-translational modifications. One of 
the most common modifications is glycosylation, which affects protein structure and function. A well 
suited glycoprotein model is immunoglobulin G (IgG), the most abundant immunoglobulin circulating 
in blood [1], as its functional importance and physiological significance has previously been described 
[1, 2]. Two identical heavy and light chains, respectively, form the IgG polypeptide backbone [3]. The 
hinge region connecting the antigen-binding part (Fab) with the crystallizable region (Fc) part of IgG 
is the most variable component and mainly differentiates the IgG subclasses (IgG1, IgG2, IgG3 and 
IgG4) [3].  
All IgG molecules contain a conserved N-glycosylation site on the Fc portion that controls pro- and 
anti-inflammatory functions of the glycoprotein [4, 5]. Additionally, about 15 to 25% of IgG molecules 
contain N-linked glycans in the Fab domain with several functions of their own [6]. The composition 
of the attached glycans is itself influenced by several factors, such as enzymes and the availability of 
precursors. N-glycan remodeling happens in the Golgi and the endoplasmic reticulum (ER) [7] and 
underlies the interaction of donor molecules, co-factors and enzymes including glycosyltransferases 
and glycosidases [8]. 
The complex interaction needed to compose the final functional glycan structure therefore cannot 
be encoded by a single gene or a combination of genes [8]. Still, the outcome of the enzymatic 
activities is well regulated and several genes encoding glycosyltransferases have been shown to 
associate with differing IgG glycosylation patterns [9]. 
While genetic regulation of the glycosylation synthesis could be partially elucidated [10, 11], the 
impact of epigenetics on IgG glycosylation is still not sufficiently studied. However, it is widely 
accepted and supported by different studies that the environment and, consequently, epigenetics 
plays an important role for the N-glycome [8, 12-15]. Additionally, it has been reviewed in [14] and 
[15] that epigenetic mechanisms have a key function in the IgG glycosylation pathway.  
DNA methylation is one of the best studied epigenetic regulations leading to differential gene 
expression  [16-18], especially gene silencing due to heavy methylation [19, 20]. Associations 
between DNA methylation and several physical and environmental factors, including smoking [21], 
lipid levels [22, 23] and physical activity [24], have been established over the last years. Indeed, using 
Mendelian randomization, it was recently shown that an altered DNA methylation status results from 
variations of blood lipid levels [23], highlighting the direction of causation for specific blood lipid 
levels. IgG glycosylation compositions have been shown to be altered in several diseases [25], 
including cancer [26, 27] and to change with age and hypertension as well as with smoking and with 
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other environmental influences [28, 29]. Effects of DNA methylation on genes involved in IgG glycan 
synthesis [30] and on the global N-glycan profile have especially been found in cancer [31, 32]. 
By analyzing the relation between DNA methylation and IgG glycans, we aim to immerse deeper into 
the epigenetic regulation of IgG glycosylation.  
In this study, we compare epigenome-wide analyses conducted in four cohorts, two cohorts for each 
IgG glycan panel including 609, 148, 619 and 1,630 samples, respectively. The glycans measured by 
ultra-performance liquid chromatography (UPLC) reflect IgG glycosylation from both Fab and Fc 
parts, while the measurements obtained by liquid chromatography electrospray mass spectrometry 
(LC/MS) describe the glycan structures at the Fc part of the IgG glycopeptides, separately for each 
subclass. We discuss the results separately for the two panels and combine the two approaches by 
analyzing their shared epigenetic associations. Furthermore, we conduct a mediation analysis for one 
cohort per glycan panel to delineate the relation of IgG glycans, DNA methylation and smoking.  
With this study we hope to elucidate the role of epigenetics in the entangled pathway leading to 
definite regulatory IgG glycan compositions.  
Methods 
Figure 1 summarizes the initial analysis steps as well as the additional mediation analysis. In total, 
3,200 samples were available for our analyses. We studied two different methods of IgG 
glycosylation, UPLC (left/blue side in Figure 1) and LC/MS (right/green side in Figure 1). UPLC data 
was available in TwinsUK (UK adult twin registry; n = 877) [33] and EGCUT (Estonian Genome Center, 
University of Tartu; n = 148) [34], while LC/MS was available in KORA F4 (Cooperative Health 
Research in the Augsburg Region; n = 1,630) [35] and LLS (Leiden Longevity Study; n = 619) [36]. The 
overlapping results from both IgG glycan panels are presented in the middle of Figure 1 and are 
followed by the results from the additional mediation analysis. 
Study Cohorts 
General Characteristics on the four cohorts are summarized in table S1. 
Cooperative Health Research in the Augsburg Region (KORA F4) 
The KORA F4 study, conducted in 2006-2008, is an independent population-based health survey [35]. 
The study followed the recommendations of the Declaration of Helsinki and was approved by the 
local ethical committees. 
Information on sociodemographic variables including sex, age, BMI (in kg/m²) was collected by 
trained medical staff during a standardized interview. White blood cell count (WBC) was measured 
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from whole blood plasma and estimated white blood cell proportions were obtained using the 
method by Houseman et al. [37]. By definition the cell proportions sum up to one, so we excluded 
from the analysis the least common cell type (NK) with the lowest mean to avoid confounding.  
In KORA F4, a total of 3,080 persons participated of whom 1,630 have both DNA methylation and IgG 
glycopeptides measured. For the mediation analysis in KORA F4, we had 1,594 samples with known 
smoking status including 671 non-smokers and 923 ever smokers (691 former smokers and 232 
current smokers). 
Leiden Longevity Study (LLS) 
The study protocol of LLS was approved by the local medical ethical committee and the study was 
conducted according to the recommendations of the Declaration of Helsinki. Written informed 
consent was obtained from all study participants. LLS collected data on long-lived individuals, their 
offspring and the partners of the offspring, as controls [36]. For this current study offspring and 
controls persons have been analyzed (n=619, mean age 59.2 years (range 39-81 years)) with both 
DNA methylation and IgG glycosylation data available [38].  
UK adult twin registry (TwinsUK) 
The TwinsUK cohort  includes more than 13,000 monozygotic and dizygotic twin volunteers from all 
regions across the United Kingdom. Volunteers were not recruited on the basis of any specific trait or 
disease and have been shown to have diseases and lifestyle characteristics similar to the general 
population [33, 39] cohort. DNA methylation was measured for 877 randomly selected individuals, 
from which 609 had information on glycan measurements. White blood cell proportions were 
estimated using the method by Houseman et al. [37]. 
Estonian Genome Center, University of Tartu (EGCUT) 
The Estonian Genome Center at the University of Tartu (EGCUT) [34] is a population based biobank 
which comprises health, genealogical and ‘omics’ data of close to 52,000 individuals ≥ 18 years of 
age, closely reflecting the age distribution in the adult Estonian population [34]. The collection of 
blood samples and the data is conducted according to the Estonian Human Gene Research Act and all 
participants have signed a broad informed consent.  
Participants of the EGCUT have been recruited by clinicians at their offices or data collectors at 
recruitment offices of the EGCUT. A computer assisted personal interview was completed for each 
participant, including personal data (place of birth, place(s) of living, nationality etc.), genealogical 
data (family history, three generations), educational and occupational history and lifestyle data 
(physical activity, dietary habits, smoking, alcohol consumption, quality of life).  
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A blood sample was drawn from each participant during the recruitment. Estimated white blood cell 
proportions were obtained using the method by Houseman et al. [37]. 
In total, 148 individuals have both DNA methylation and IgG glycan measurements. They were 
selected from a subgroup of “healthy” individuals who have been re-contacted for a second time-
point interview, a subgroup of individuals that died of cancer within five years since recruitment 
(„healthy“ at baseline), and a subgroup of men diagnosed with prostate cancer within five years 
since recruitment („healthy“ at baseline). Of them, 45 are current, 39 former and 64 never-smokers. 
DNA isolation and preparation  
A blood sample was drawn from each participant during the recruitment and DNA was isolated using 
standard procedures. DNA methylation was analyzed with the Illumina HumanMethylation450K 
BeadChip [40]. Preceding treatment of the blood samples followed the manufacturer’s guidelines. 
DNA methylation data were measured with the Illumina HumanMethylation450K BeadChip [40] in all 
four cohorts. 
DNA Methylation Preprocessing 
Methylation data from all studies underwent specific initial quality control. Beta-values of DNA 
methylation as well as appropriate technical covariates were included in the statistical models. 
Family structure was accounted for if needed. 
For KORA F4, processing of the raw DNA methylation data and initial quality control was 
accomplished as described in detail in [21]. Following, data from KORA F4 and EGCUT followed the 
quantile normalization pipeline described by Lehne et al [41]. The pipeline includes a background 
correction, a detection p-value threshold of 0.01 and a sample callrate of 95%. Quantile 
normalization of the intensity values was performed and beta-values for methylation were used for 
further analyses. Markers on both X and Y chromosomes had been excluded at the time of the 
analysis. To avoid technical confounding a principle component analysis (PCA) was performed for the 
positive control probes of the BeadChip. Both the first 20 control probe PCAs as well as white blood 
cell composition proportions were calculated and used in the final model. No callrate threshold for 
CpG-sites was used. 
Data from TwinsUK underwent an initial quality control including e.g. a detection p-value > 0.05 and 
the exclusion of DNA methylation probes that mapped incorrectly or to multiple locations. Following, 
the data were beta-mixture quantile normalized as described in [42].   
For LLS, the generation of genome-wide DNA methylation data is described by Bonder et al [43]. The 
original idat files were generated by the Illumina iScan BeadChip scanner. Subsequently, sample 
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quality control was performed using MethylAid [44]. Similar to the pipeline used for the other 
cohorts, probes with a high detection p-value (> 0.01), probes with a low bead count (< 3 beads), and 
probes with a low success rate (missings in > 95 %) were excluded from the analysis. Subsequently, 
imputation was performed to impute the missing values. Functional normalization, as implemented 
in the minfi package, was used. 
 
Measurement of IgG Glycosylation 
The two different methods applied, UPLC and LC/MS as well as the single process steps applied have 
been described in detail in  [9, 11, 45-47]. In short, for both analytical methods, IgG was first isolated 
from plasma as presented in [9]. 
For KORA F4 and LLS, glycosylation patterns were examined by the analysis of tryptic glycopeptides 
using the nanoLC-ESI-MS (denoted as LC/MS) method as outlined in [46] which provides subclass-
specific glycoforms. Due to their similar peptide moieties however, IgG2 and IgG3 cannot be 
distinguished in Caucasian [48] and will be denoted by IgG2/3 or simply IgG2 in the following. For LLS, 
IgG was isolated by protein A, which does not bind to IgG3, so IgG2 data represents pure IgG2 
subclass. More details on the analytical method can be found in [47]. In total, 20 glycoforms could be 
observed for both IgG1 and IgG2/3, and 10 peaks describing fucoslyated glycoforms for IgG4. 
Glycan profiles for TwinsUK and EGCUT, were investigated by UPLC after IgG isolation and IgG N-
glycan release and labeling. Details are provided in [9, 45, 47]. In total, 24 glycan peaks can be 
distinguished by this approach. For TwinsUK however, the peaks of GP20 and GP21 (see table S2a for 
details) were not uniquely distinguishable and both traits are excluded in the downstream analysis. 
Summarizing, LC/MS measurements provide data on the glycan structure attached to the Fc part of 
IgG glycopeptides. UPLC data in contrast contain information on the total released IgG glycans from 
both Fab and Fc parts. 
IgG Glycan Preprocessing 
Both UPLC and LC/MS measured IgG N-glycans were total area normalized as implemented in the R-
package ‘glycanr’ v0.3.0  [49]. We consider glycan percentages for UPLC and glycan percentages per 
subclass for LC/MS data. Normalization was followed by log-transformation and batch correction 
(per subclass for LC/MS data) using the ComBat algorithm [50] of the R package ‘sva’ v3.14.0 [51]. In 
order to recapture the initial scale, the data were exponentiated and then derived traits were 
calculated as provided by the glycanr-package [49] and as in [45]. See the tables S2a and S2b for an 
overview of initial and derived traits for both UPLC and LC/MS data. To ensure normal distribution of 
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the phenotypes, data were inverse normal rank transformed [52]. For similar derived traits however, 
the normal rank transformation led to the exactly same values for differing traits (e.g. LC_IGP42 and 
LC_IGP44; LC_IGP43 and LC_IGP45 in the KORA F4 cohort). We kept those similar traits and flagged 
them within each cohort separately. 
Statistical Methods 
Primary EWAS analysis 
In each cohort we performed linear regression models for all glycan traits with each glycan as 
outcome. Beta-values of DNA methylation entered the model as independent variables. To account 
for confounding, we adjusted the model by age, sex, BMI, white blood cell count (WBC) (available 
only in KORA F4), estimated white blood cell proportions and technical covariates if applicable. 
Different software was used for the initial computation of the linear model (KORA F4: omicABEL [53], 
LLS: R-package cate v1.0.4 [54], TwinsUK and EGCUT: R (3.2.2) [55]). 
Meta-analysis 
For UPLC and LC/MS data respectively, we performed a random effects meta-analysis using the 
package 'metafor' [56] from the statistical software R (Version 3.2.1). Inverse variance weighting and 
the restricted maximum likelihood estimator were used for the analysis. 
We excluded six glycan traits (LC_IGP170, LC_IGP148, LC_IGP147, LC_IGP149, LC_IGP107, LC_IGP150) 
in the LC/MS dataset due to their deviating QQplots (an example is shown in supplemental figure 1) 
in the meta-analysis in order to reduce bias from measurement errors. Additionally, these traits 
showed an uncommonly large number of associations (> 5,000) randomly across the genome. 
We set the Bonferroni-corrected [57] epigenome-wide significant p-value threshold for UPLC data at 
4.6 x 10-9 (0.05/ 450,000 CpG-sites / 24 initially measured glycans) and at 2.2 x 10-9 for LC/MS data 
(0.05/ 450,000 CpG-sites / 50 initially measured glycans). As suggestive threshold for both panels, we 
used 1.1 x 10-7 (0.05/ 450,000 CpG-sites). In order to assure stability of the results, we additionally 
excluded 248 combinations with differing effect directions and p-values for an individual study larger 
than 0.05 from the meta-analysis results (between 43 IgG glycan traits and 137 CpG-sites). A full list 
of all associations before exclusion can be found in table S4b. 
To combine the results from both meta-analyses, we took all suggestive CpG-sites (p < 1.1 x 10-7) 
from both panels and analyzed their associations with IgG glycan traits with p-values below 0.001 in 
the other panel, respectively. For further analyses, we focused on CpG-sites that were suggestive in 
one meta-analysis and had a maximal p-value of 0.001 for any association within the other glycan 
panel. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Mediation analysis 
CpG-sites and their associated IgG glycans remaining after the exclusion criteria were further used in 
a mediation analysis with respect to smoking. We performed Sobel tests [58, 59] to assess the 
mediation effect and performed an analysis of variance for the appropriate CpG - glycan 
combinations. All analyses were conducted in R by using the package ‘bda’ v5.1.6 [60] and the 
functions sobel.test and aov (‘stats’ v3.4.0 [55]). We differentiated between ever smokers (current or 
former smokers) and never smokers. While smoking status was considered as independent variable, 
the CpG-site entered the model either as mediator or as dependent variable whereas the glycan trait 
fulfilled the remaining task, correspondingly. With these two approaches we want to examine the 
direction of the mediation. The p-value thresholds for the UPLC and LC/MS dataset follow the 
Bonferroni-correction [57] and were set to 0.017 (0.05/ 3 combinations) and 6.8 x 10-4 (0.05/ 74 
combinations), respectively (see Table 2a and 2b for additional information on the selected 
combinations).  
Results 
Figure 1 displays the analysis workflow for the identification of associations between CpG-sites and 
IgG glycosylation traits. 
For the UPLC meta-analysis, we found in total 124 associations between 27 glycan traits and 26 CpG-
sites to be at least suggestively significant at Bonferroni-correction (p < 1.1 x 10-7, Bonferroni-
corrected for number of CpG-sites).  Out of these associations, 61 were epigenome-wide significant 
(p < 4.6 x 10-9, Bonferroni-corrected for the number of CpG-sites and the number of initial measured 
UPLC glycan traits) associations corresponding with 7 CpG-sites and 14 glycan traits (Figure 1, table 
S3).  
For the LC/MS data, we found in total 6 suggestive (p < 1.1 x 10-7, Bonferroni-corrected for number of 
CpG-sites) associations between 4 CpG-sites and 3 glycan traits (Figure 1, table S4a). Of these 
associations, 2 were epigenome-wide significance threshold of p < 2.2 x 10-9 (Bonferroni-corrected 
for the number of CpG-sites and the number of initial measured LC/MS glycopeptides), i.e. 
cg0612642: p(LC_IGP43) = 8.82 x 10-13, p(LC_IGP45) = 1.01 x 10-12. 
 
Combining the results from the 26 CpG-sites from the UPLC glycan panel and the 4 CpG sites from 
the LC/MS glycan panel yields 28 unique CpG-sites, out of which 7 CpG-sites are suggestive (p < 1.1 x 
10-7) for one glycan panel and have at least one association with p < 0.001 in the other glycan panel.  
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Of the 7 CpG sites (Figure 1, table T1), 6 CpG sites associated with 20 UPLC glycan trait and 3 CpG 
sites with 2 LC/MS IgG glycan traits (Table S5a and S5b). Two CpG-sites are suggestively significant for 
both glycan panels, cg05951221 and cg21566642 (both on chromosome 2).  
The 7 CpG-sites are located on 5 genomic locations: cg25189904 on chromosome 1 (1:68,299,493; 
1p31.3, GNG12); cg05951221, cg21566642, cg01940273 on chromosome 2 (2:233,284,402 – 2: 
233,284,934; 2q37.1, close to ALPPL2 [61]) from which the first two are suggestive for both glycan 
panels; cg05575921 on chromosome 5 (5: 373,378; 5p15.33; AHRR); cg06126421 on chromosome 6 
(6:30,720,080; 6p21.33); and cg03636183 on chromosome 19 (19: 17,000,585; 19p13.11, F2RL3). 
The 3 CpG-sites on chromosome 2 are in very close proximity and belong to the same CpG Island 
located at chr2:233,283,398-233,285,959. Thus, we assume only one independent signal on 
chromosome 2. 
For the UPLC IgG traits, 20 IgG glycan traits exhibit similar association to the CpG-sites and they 
mostly represent the percentage of fucosylation with and without bisecting GlcNAc, as well as the 
ratio between structures containing a bisecting GlcNAc and lacking a bisecting GlcNAc.  
The associated IgG glycans in the LC/MS panel are 2 derived traits, LC_IGP43 and LC_IGP45, which 
can be described them as the relation of fucosylated monosialylated structures with bisecting GlcNAc 
to all fucosylated and monosialyated structures within IgG1. 
In general, a decrease of DNA methylation at the CpG-sites on chromosome 1, 2, 5 and 19 is 
associated with an increase of structures with bisecting GlcNAc compared to structures without 
bisecting GlcNAc. 
Mediation Analysis 
Since the methylation at all 7 CpG-sites associating significantly with IgG glycosylation traits (Figure 1) 
have been reported to be associated with smoking status [21, 62-67], we tested whether 1) IgG 
glycosylation is a mediator in the association between smoking and DNA methylation, or whether 2) 
DNA methylation is a mediator in the association between smoking and IgG glycosylation.  For the 
UPLC data, 6 CpG-sites have been tested for their association with 20 IgG glycan traits (74 
associations) in the EGCUT study, while for LC/MS data 3 CpG-sites have been tested for their 
associations with 2 IgG glycan traits (3 unique associations) in the KORA F4 study. 
For the UPLC data in EGCUT, we analyzed 74 IgG glycan – CpG combinations in EGCUT. In total, 64 
non-smokers and 84 ever smokers were available. The mediation between smoking and IgG via the 
CpG-sites (p-values range between 2.3 x 10-4 to 0.15, table T2a)  is stronger than the mediation 
between smoking and CpG via IgG (p-values range between 8.3 x 10-3 to 0.27, table T2b). The 
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mediation of the associations between smoking and IGP39 and IGP40 via the CpG-site cg21566642 is 
Bonferroni-corrected significant (p < 6.8 x 10-4, table T2a). 
The mediation analysis in KORA F4 was conducted on 1,594 samples including 671 non-smokers and 
932 ever smokers. For all three CpG-sites (cg05951221, cg21566642 and cg06126421), the mediation 
effect of DNA methylation on the association between smoking and IgG glycosylation was significant 
(p-values range between 1.3 x 10-8 to 1.4 x 10-3) (table T2a) while the significance of the mediation 
effect of the glycans was comparably lower (table T2b). An additional analysis of variance confirmed 
that the adjustment for the CpG-site in the smoking - IgG glycan model is significant for all 3 CpG-
sites (p = 1.5 x 10-3, p = 1.8 x 10-4, p = 1.3 x 10-8). The CpG-sites increase the explained variance of the 
variation of IgG glycan by 0.52 %, 0.69 % and 0.8 %, respectively (table T2a). 
A summarizing plot of the mediation analysis is given in Figure 2. These results hint at a possible 
mediating effect of DNA methylation on the relation between smoking and IgG glycosylation. 
Discussion 
In the current paper, we aimed at identifying methylation levels of CpG-sites to be associated with 
IgG glycosylation traits. We conducted meta-analyses for UPLC IgG glycan data (n = 757) and LC/MS 
IgG glycan data (n = 2,249) using data from four cohorts (LLS, KORA F4, EGCUT, TwinsUK) and around 
3,000 samples contributing to our study. We found 7 CpG-sites associating with IgG glycosylation 
traits. Out of these, 6 CpG-sites on chromosome 1, 2, 5, and 19 are associated with an increase of 
structures with bisecting GlcNAc compared to structures without bisecting GlcNAc (UPLC data). 
Additionally, we found 3 CpG-sites on chromosome 2 and 6 of which a decrease in DNA methylation 
is associated with an increase of IgG1 fucosylated monosialylated structures with bisecting GlcNAc 
compared to all fucosylated and monosialylated IgG1 structures (LC/MS data). Two CpG-sites on 
chromosome 2, cg05951221 and cg21566642, associate with both UPLC as LC/MS IgG glycan traits. 
 
 
that are suggestive (p < 1.1 x 10-7) in at least one panel (table T1) and show associations with p < 
0.001 in the other. Out of these, 2 CpG-sites reached the significance threshold of 10-7 in both panels. 
In depth mediation analysis revealed that the effect of smoking on IgG glycosylation levels is 
mediated by the identified 7 CpG-sites on chromosome 1, 2, 5, 6, and 19. 
In fact, all 7 CpG-sites on chromosome 1 (GNG12), chromosome 2 (ALPPL2), chromosome 5 (AHRR), 
chromosome 6 (6p21.33) and chromosome 19 (F2RL3) have been determined to be highly influenced 
by smoking [21, 62-67]. Strikingly, one of the studies [63] found the genes implicated in the 
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association of DNA methylation and smoking to be enriched for biological functions related to the 
immune response, e.g. ‘regulation of T-helper 2 cell differentiation’. Similarly, smoking has been 
shown to reshape the glycemic profile by different analytical methods [68, 69], in particularly 
including associations to the N-glycome [70] and IgG glycosylation [29]. 
Additionally, smoking has been associated with increased branching of glycan structures [29]. 
Through the mediation analysis for all 7 CpG-sites, we can hypothesize that smoking leads to a higher 
ratio between IgG glycan structures with bisecting GlcNAs compared to structures without bisecting 
GlcNAs, i.e. an increased branching of IgG glycopeptides, via a decrease of DNA methylation at these 
CpG-sites. For the LC/MS data, we can specify the structure to be additionally fucosylated and 
monosialylated. None of the loci has been associated to IgG glycosylation before, especially not in a 
hypothesis-free genome-wide analysis. The effect of these CpG-sites thus may have a specific role in 
the interaction of smoking and IgG glycosylation [11]. 
On chromosome 1, the CpG-site cg25189904 is located within the region of GNG12-AS1, a GNG12 
antisense RNA 1. Its antisense orientation to the gene DIRAS3 causes the transcriptional silencing of 
GNG12-AS1 to upregulate the expression of the tumor-suppressor gene DIRAS3, a process which in 
turn undermines cell cycle progression [71]. However, other studies that found this CpG-site to be 
highly associated with smoking [21, 62, 63]  claim the annotation of cg25189904 to the gene GNG12 
(G protein subunit gamma 12). In addition, the CpG-site is directly annotated to GNG12 by the 
manufacturer. Here, further functional studies are recommended to assess the effect of the CpG-site 
on gene expression and, in a broader sense, on IgG glycosylation. 
The 3 CpG-sites on chromosome 2, cg05951221, cg21566642, cg01940273, are located in proximity 
(233,284,402 – 233,284,402, 2q37.1) of the genes that belong to the group of alkaline phosphatases 
[61], with ALPPL2 (chr2:233,271,552-233,275,424) being the closest gene. The encoded glycosylated 
enzyme is extensively expressed in tumors [72] and could be associated with pancreatic carcinoma 
[73] and, in one case, with ovarian cancer [73, 74]. 
Effects for CpG-sites on AHRR on chromosome 5, an aryl-hydrocarbon receptor repressor, have been 
markedly shown in white blood cells [75, 76], including precursors of B-cells which produce 
immunoglobulin G. Additionally, it could be proven that DNA methylation of cg05575921 in cord 
blood of newborns is affected by prenatal influences, including maternal smoking behavior and BMI 
[77, 78]. IgG is transported actively to the fetus via the placenta [79] in order to provide 
immunological protection for the fetus and newborn. Differences between maternal and cord blood 
glycosylation for both IgG and the total plasma N-glycome have been shown recently [80] and 
specific N-glycans could be associated to a poor fetal environment [81]. A direct link between 
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glycosylation and DNA methylation in cord blood is however still missing. Given our results, there 
might be an interesting association. 
The gene F2RL3 on chromosome 19 encodes a protease-activated receptor that plays an important 
role in blood coagulation and the pathogenesis of inflammation [82] and pain [83]. Its pro-
inflammatory effects, however, are still not fully understood [83]. Interestingly, anti- and pro-
inflammatory functioning of IgG depends upon its glycosylation structure [1, 4, 5]. 
For CpG-sites on chromosome 5 (cg05575921, AHRR) and on chromosome 19 (cg03636183, F2RL3), 
there is strong evidence that DNA methylation mediates the effects of smoking for cardiovascular 
diseases [65, 84, 85], all-cause mortality [65, 86, 87] and cancer [88], in particular, for lung cancer 
[67, 75, 89, 90]. Nevertheless, it has been shown that several challenges including measurement 
errors, may interfere with the results of mediation analyses [91]. Thus, the results should be handled 
with caution. 
 
Limitations of our study include the low sample sizes for the mediation analyses, especially for UPLC-
measured glycan traits. Additionally, the differing analytical methods for the measurement of IgG 
glycosylation complicate the joint interpretation of the associated IgG glycan traits. Both analytical 
methods employed in our analysis, LC/MS and UPLC, bear advantages and disadvantages [2, 46]. 
Based on our results, we hypothesize that there is a triangular relation between smoking, DNA 
methylation and IgG glycans, in which DNA methylation mediates the effect of smoking on IgG 
glycosylation. We detect an increase in IgG glycan branching, especially a relative increase of IgG 
glycan structures with bisecting GlcNAs that is associated with smoking via downregulated DNA 
methylation. While it is to a large extent known how smoking affects DNA methylation, the 
connection to IgG glycans represents a new part of the puzzle explaining the impact of smoking on 
the human body. Nevertheless our analysis proposes hypotheses here which is a strength of cross-
sectional studies. However we are totally aware of primary limitation of the cross-sectional studies, 
as there is no evidence of temporal relationship between exposure and outcome and has been 
assessed simultaneously. Without longitudinal data we are not establishing true cause and effect 
relationship.   
In summary, our epigenome-wide analysis of DNA methylation and IgG glycosylation revealed 
stronger results for UPLC measured data that comprise both Fab and Fc glycosylation sites than for 
LC/MS measured data including only glycoforms on the Fc part of IgG. Still, all of the associated CpG-
sites have been exemplified to be highly influenced by smoking. The conducted mediation analysis 
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confirms that, at least for two CpG-sites, the effect of smoking on IgG glycosylation, is mediated by 
DNA methylation. We therefore recommend further studies in order to unfold the interaction of the 
three components. 
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Table 1 
Overview on suggestive CpG-sites form one panel and p < 0.001 in the other 
 
CpG 
Chro
moso
me 
posit
ion 
reference 
gene 
Minimal p-
value for 
the CpG-
site in 
UPLC 
meta-
analysis 
Number of 
suggestivel
y 
associated 
UPLC traits 
Associated UPLC IgG Glycan 
Traits 
Minimal p-value 
for the CpG-site 
in LC/MS meta-
analysis 
Number of 
suggestively 
associated LC/MS 
traits 
Associated 
LC/MS IgG 
Glycan Traits 
cg251
8990
4 
1p31.
3 
6829
9493 GNG12 7.49E-09 3 IGP49, GP10, IGP68 6.78E-04 0  
cg059
5122
1 
2q37.
1 
2332
8440
2  8.68E-12 13 
IGP66, IGP68, IGP62, GP10, 
IGP63, IGP70, IGP72, IGP67, 
IGP39, IGP40, IGP49, IGP71, 
IGP64 1.08E-08 2 
LC_IGP43, 
LC_IGP45 
cg215
6664
2 
2q37.
1 
2332
8466
1  3.71E-14 16 
IGP66, IGP75, IGP74, IGP69, 
IGP62, IGP71, IGP65, IGP39, 
GP10, IGP76, IGP70, IGP40, 
IGP49, IGP68, IGP64, IGP72 2.97E-09 1 LC_IGP43 
cg019
4027
3 
2q37.
1 
2332
8493
4  1.24E-11 16 
IGP70, IGP39, IGP62, IGP68, 
IGP40, IGP67, IGP75, IGP64, 
IGP66, IGP63, IGP71, IGP74, 
IGP69, GP10, IGP49, IGP72 4.91E-07 0  
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
cg055
7592
1 
5p15.
33 
3733
78 AHRR 3.79E-14 13 
GP23, GP10, IGP64, IGP70, 
IGP34, IGP39, IGP40, IGP62, 
IGP66, IGP68, IGP71, IGP72, 
IGP49 7.85E-05 0  
cg061
2642
1 
6p21.
33 
3072
0080  5.25E-07 0  8.82E-13 2 
LC_IGP43, 
LC_IGP45 
cg036
3618
3 
19p13
.11 
1700
0585 F2RL3 7.92E-11 13 
IGP62, IGP63, IGP72, IGP71, 
IGP67, IGP40, IGP39, IGP49, 
IGP66, IGP64, IGP70, GP10, 
IGP68 7.43E-07 0  
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Table 2a 
 
Results for Mediation Analysis in KORA and EGCUT with the CpG-site as potential mediator 
 
CpG as Mediator 
LC/MS: threshold = 0.017     Anova: IgG ~ CpG + smoking + covariates 
IgG glycan trait CpG p (Sobel-test) 
Additional Variance 
Explained  
by the CpG-site (R2) p-value of CpG-site 
LC_IGP43 cg05951221 0.001485682 0.005210657 0.002618943 
LC_IGP45 cg05951221 0.001485682 0.005210657 0.002618943 
LC_IGP43 cg21566642 0.000177866 0.006896529 0.000532924 
LC_IGP43 cg06126421 1.31713E-08 0.008021274 0.00018653 
LC_IGP45 cg06126421 1.31713E-08 0.008021274 0.00018653 
 
 
UPLC: threshold = 6.8e-04     Anova: IgG ~ CpG + smoking + covariates 
IgG glycan trait CpG p (Sobel-test) 
Additional Variance 
Explained  
by the CpG-site (R2) p-value of CpG-site 
IGP49 cg25189904 0.062994361 0.05416807 0.002419576 
GP10 cg25189904 0.061991431 0.058431596 0.00158616 
IGP68 cg25189904 0.014448871 0.072188424 0.000291678 
IGP66 cg05951221 0.022542464 0.031150223 0.020818396 
IGP68 cg05951221 0.004971857 0.041564239 0.006627828 
IGP62 cg05951221 0.033277717 0.036814666 0.014137276 
GP10 cg05951221 0.044336053 0.022948982 0.050797773 
IGP63 cg05951221 0.098521911 0.026457082 0.045463986 
IGP70 cg05951221 0.026530856 0.030814716 0.021918835 
IGP72 cg05951221 0.025005668 0.030895214 0.021911266 
IGP67 cg05951221 0.125752028 0.015437522 0.119278616 
IGP39 cg05951221 0.009511351 0.026275257 0.021771215 
IGP40 cg05951221 0.009511351 0.026275257 0.021771215 
IGP49 cg05951221 0.035970392 0.022213343 0.054940179 
IGP71 cg05951221 0.026530856 0.030814716 0.021918835 
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IGP64 cg05951221 0.005114167 0.049276526 0.003428988 
IGP66 cg21566642 0.006203155 0.035856714 0.012984802 
IGP75 cg21566642 0.005538572 0.037931321 0.010702606 
IGP74 cg21566642 0.005538572 0.037931321 0.010702606 
IGP69 cg21566642 0.00722555 0.035384995 0.014334399 
IGP62 cg21566642 0.008943166 0.044057296 0.007115189 
IGP71 cg21566642 0.007351238 0.035691951 0.013471837 
IGP65 cg21566642 0.006878152 0.053019324 0.002910797 
IGP39 cg21566642 0.000236086 0.038360744 0.005315167 
GP10 cg21566642 0.03613135 0.024624397 0.042921596 
IGP76 cg21566642 0.009187717 0.035152957 0.014955653 
IGP70 cg21566642 0.007351238 0.035691951 0.013471837 
IGP40 cg21566642 0.000236086 0.038360744 0.005315167 
IGP49 cg21566642 0.028970152 0.02431183 0.044483128 
IGP68 cg21566642 0.001709601 0.043391679 0.00550254 
IGP64 cg21566642 0.001819179 0.050451186 0.00305211 
IGP72 cg21566642 0.007768163 0.034891509 0.014715385 
IGP70 cg01940273 0.013437126 0.030102714 0.02354151 
IGP39 cg01940273 0.010470556 0.021393124 0.038850408 
IGP62 cg01940273 0.008795505 0.037359917 0.013422772 
IGP68 cg01940273 0.005353127 0.035522961 0.012281103 
IGP40 cg01940273 0.010470556 0.021393124 0.038850408 
IGP67 cg01940273 0.062134358 0.018057553 0.091727474 
IGP75 cg01940273 0.041690728 0.015360187 0.107314591 
IGP64 cg01940273 0.004359403 0.039945194 0.008657255 
IGP66 cg01940273 0.01323863 0.030761408 0.021650035 
IGP63 cg01940273 0.025732389 0.03198015 0.027572525 
IGP71 cg01940273 0.013437126 0.030102714 0.02354151 
IGP74 cg01940273 0.041690728 0.015360187 0.107314591 
IGP69 cg01940273 0.064934023 0.013377681 0.135331853 
GP10 cg01940273 0.034666225 0.023150314 0.049776663 
IGP49 cg01940273 0.025878659 0.023509451 0.048212699 
IGP72 cg01940273 0.013928045 0.029413125 0.025417003 
GP23 cg05575921 0.151679974 0.03157825 0.019449147 
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GP10 cg05575921 0.003856893 0.049063578 0.00392826 
IGP64 cg05575921 0.001173097 0.055445413 0.001860242 
IGP70 cg05575921 0.004529522 0.03891391 0.009784855 
IGP34 cg05575921 0.004731005 0.046174244 0.004448482 
IGP39 cg05575921 0.024012772 0.016151229 0.073325842 
IGP40 cg05575921 0.024012772 0.016151229 0.073325842 
IGP62 cg05575921 0.010054398 0.041846723 0.008770027 
IGP66 cg05575921 0.003995263 0.038752123 0.009726404 
IGP68 cg05575921 0.000804767 0.052738094 0.002127067 
IGP71 cg05575921 0.004529522 0.03891391 0.009784855 
IGP72 cg05575921 0.004621036 0.038931538 0.009862206 
IGP49 cg05575921 0.002434214 0.045591847 0.005541803 
IGP62 cg03636183 0.056134614 0.014525275 0.126262611 
IGP63 cg03636183 0.050343218 0.017509706 0.104701109 
IGP72 cg03636183 0.029463857 0.01801353 0.081572755 
IGP71 cg03636183 0.029586753 0.018398182 0.077966265 
IGP67 cg03636183 0.024531846 0.020042005 0.075432295 
IGP40 cg03636183 0.139397648 0.013089355 0.107401217 
IGP39 cg03636183 0.139397648 0.013089355 0.107401217 
IGP49 cg03636183 0.007802105 0.035516613 0.014731495 
IGP66 cg03636183 0.026773576 0.019837948 0.066271513 
IGP64 cg03636183 0.016032079 0.02476639 0.039853874 
IGP70 cg03636183 0.029586753 0.018398182 0.077966265 
GP10 cg03636183 0.01475222 0.035095594 0.015254734 
IGP68 cg03636183 0.010868436 0.029333674 0.023214205 
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Table 2b 
 
Results for Mediation Analysis in KORA and EGCUT with the IgG glycan as potential mediator 
 
IgG as Mediator 
LC/MS: threshold = 0.017     Anova: CpG ~ IgG + smoking + covariates 
IgG glycan trait CpG p (Sobel-test) 
Additional Variance 
Explained  
by the IgG glycan 
traits (R2) p-value of the IgG glycan trait 
LC_IGP43 cg05951221 0.091766616 0.004234085 0.002618943 
LC_IGP45 cg05951221 0.091766616 0.004234085 0.002618943 
LC_IGP43 cg21566642 0.078966329 0.005259427 0.000532924 
LC_IGP43 cg06126421 0.059804893 0.005910232 0.00018653 
LC_IGP45 cg06126421 0.059804893 0.005910232 0.00018653 
 
 
UPLC: threshold = 6.8e-04     Anova: CpG ~ IgG + smoking + covariates 
IgG glycan trait CpG p (Sobel-test) 
Additional 
Variance 
Explained  
by the IgG 
glycan traits 
(R2) p-value of the IgG glycan trait 
IGP49 cg25189904 0.143197057 0.047336711 0.002419576 
GP10 cg25189904 0.158870739 0.051154534 0.00158616 
IGP68 cg25189904 0.035416491 0.066390015 0.000291678 
IGP66 cg05951221 0.063062909 0.016891058 0.020818396 
IGP68 cg05951221 0.024648278 0.023103555 0.006627828 
IGP62 cg05951221 0.083614538 0.018982066 0.014137276 
GP10 cg05951221 0.14743234 0.012142933 0.050797773 
IGP63 cg05951221 0.20876835 0.012725983 0.045463986 
IGP70 cg05951221 0.067909783 0.016613844 0.021918835 
IGP72 cg05951221 0.067515719 0.016615701 0.021911266 
IGP67 cg05951221 0.208154303 0.007771197 0.119278616 
IGP39 cg05951221 0.032333138 0.016650195 0.021771215 
IGP40 cg05951221 0.032333138 0.016650195 0.021771215 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
IGP49 cg05951221 0.12154544 0.01173255 0.054940179 
IGP71 cg05951221 0.067909783 0.016613844 0.021918835 
IGP64 cg05951221 0.025891032 0.026703995 0.003428988 
IGP66 cg21566642 0.037347592 0.01644872 0.012984802 
IGP75 cg21566642 0.022716844 0.017336831 0.010702606 
IGP74 cg21566642 0.022716844 0.017336831 0.010702606 
IGP69 cg21566642 0.026375984 0.01599519 0.014334399 
IGP62 cg21566642 0.049717893 0.019217921 0.007115189 
IGP71 cg21566642 0.039527675 0.016279767 0.013471837 
IGP65 cg21566642 0.044260365 0.023349157 0.002910797 
IGP39 cg21566642 0.008294586 0.020564839 0.005315167 
GP10 cg21566642 0.139027246 0.011022794 0.042921596 
IGP76 cg21566642 0.038090025 0.01580078 0.014955653 
IGP70 cg21566642 0.039527675 0.016279767 0.013471837 
IGP40 cg21566642 0.008294586 0.020564839 0.005315167 
IGP49 cg21566642 0.113575514 0.010863308 0.044483128 
IGP68 cg21566642 0.016183057 0.020404755 0.00550254 
IGP64 cg21566642 0.017360292 0.023129885 0.00305211 
IGP72 cg21566642 0.041727695 0.015874979 0.014715385 
IGP70 cg01940273 0.050349502 0.015743813 0.02354151 
IGP39 cg01940273 0.034132643 0.013150397 0.038850408 
IGP62 cg01940273 0.049738823 0.018686194 0.013422772 
IGP68 cg01940273 0.025673242 0.019154043 0.012281103 
IGP40 cg01940273 0.034132643 0.013150397 0.038850408 
IGP67 cg01940273 0.154241798 0.008817826 0.091727474 
IGP75 cg01940273 0.069952612 0.008049977 0.107314591 
IGP64 cg01940273 0.024461891 0.020998729 0.008657255 
IGP66 cg01940273 0.050226093 0.016180585 0.021650035 
IGP63 cg01940273 0.143897277 0.014921834 0.027572525 
IGP71 cg01940273 0.050349502 0.015743813 0.02354151 
IGP74 cg01940273 0.069952612 0.008049977 0.107314591 
IGP69 cg01940273 0.094859733 0.006933898 0.135331853 
GP10 cg01940273 0.13776097 0.011882542 0.049776663 
IGP49 cg01940273 0.110158559 0.01204518 0.048212699 
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IGP72 cg01940273 0.05256029 0.01534479 0.025417003 
GP23 cg05575921 0.269703323 0.017421455 0.019449147 
GP10 cg05575921 0.089344319 0.026207319 0.00392826 
IGP64 cg05575921 0.014218745 0.030332276 0.001860242 
IGP70 cg05575921 0.03238985 0.021179712 0.009784855 
IGP34 cg05575921 0.047010261 0.025521109 0.004448482 
IGP39 cg05575921 0.051370285 0.010331923 0.073325842 
IGP40 cg05575921 0.051370285 0.010331923 0.073325842 
IGP62 cg05575921 0.050680629 0.021781476 0.008770027 
IGP66 cg05575921 0.031212684 0.021212625 0.009726404 
IGP68 cg05575921 0.011848671 0.029592839 0.002127067 
IGP71 cg05575921 0.03238985 0.021179712 0.009784855 
IGP72 cg05575921 0.033922796 0.02113646 0.009862206 
IGP49 cg05575921 0.066113572 0.024309101 0.005541803 
IGP62 cg03636183 0.102587704 0.009467955 0.126262611 
IGP63 cg03636183 0.163628154 0.01064725 0.104701109 
IGP72 cg03636183 0.067341818 0.012247163 0.081572755 
IGP71 cg03636183 0.065984785 0.012539957 0.077966265 
IGP67 cg03636183 0.109371773 0.012754419 0.075432295 
IGP40 cg03636183 0.16350642 0.010485757 0.107401217 
IGP39 cg03636183 0.16350642 0.010485757 0.107401217 
IGP49 cg03636183 0.076541736 0.023714787 0.014731495 
IGP66 cg03636183 0.062792499 0.013598833 0.066271513 
IGP64 cg03636183 0.038739084 0.016967117 0.039853874 
IGP70 cg03636183 0.065984785 0.012539957 0.077966265 
GP10 cg03636183 0.107093929 0.023475884 0.015254734 
IGP68 cg03636183 0.030339903 0.020612689 0.023214205 
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